Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Indivior and increased the price target to $35.00 from $28.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brandon Folkes has given his Buy rating due to a combination of factors, including Indivior’s strong third-quarter performance that surpassed expectations and the company’s strategic cost-saving measures. The analyst highlights the potential for significant growth in Sublocade sales, driven by increased penetration of long-acting injectables (LAIs) in the opioid use disorder treatment market.
Folkes also notes that despite Indivior’s stock outperforming in 2025, it remains undervalued compared to its peers. The company’s ability to execute its commercial strategy effectively, along with the resolution of past legal challenges, supports the potential for further stock appreciation. Additionally, the possibility of entering Phase 3 of its “Breakout” plan and the attractive financial profile of Indivior position it well for future growth and potential acquisition interest.